Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia.
about
Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models.Temporal lobe structure as determined by nuclear magnetic resonance in schizophrenia and bipolar affective disorderStudies on the hippocampal formation: From basic development to clinical applications: Studies on schizophreniaCytokine and growth factor involvement in schizophrenia--support for the developmental model.Cholecystokinin: a multi-functional molecular switch of neuronal circuits.Neuropeptides involved in the pathophysiology of schizophrenia and major depression.The diagnostic validity of paraphrenia.Somatostatinergic systems: an update on brain functions in normal and pathological aging.Neuropeptides, dopamine, and schizophrenia.Cholecystokinin, dopamine, and schizophrenia: recent progress and current problems.The relationship of negative schizophrenia to parkinsonism.Interactions of cholecystokinin and dopamine in the nucleus accumbens.Cholecystokinin-2 receptor mediated gene expression in neuronal PC12 cells.Enzyme immunoassay for cholecystokinin octapeptide sulfate and its application.Merck, Sharp & Dohme Prize for Young Psychopharmacologists: A history of frontal and temporal lobe aspects of the neuropharmacology of schizophrenia.Reduced cholecystokinin levels in the limbic lobe in schizophrenia. A marker for pathology underlying the defect state?The elusive nature of cerebellar somatostatin receptors: studies in rat, monkey and human cerebellum.Possible association of a cholecystokinin promoter variant to schizophrenia.
P2860
Q30532041-F1A4D9EA-6B3A-45E1-8668-0B755DA17FDAQ33628457-27426ECF-D129-45F2-8F40-B1F48A21A9FFQ33691327-95CF0FF4-9AF3-4B57-94DD-5E155AB79A16Q34111013-4F26485B-A9A9-4D14-9DD6-5E7412E87569Q34420892-37078612-2CD4-43DC-B239-31C21D84E5A3Q35130197-DB9ED9D3-4287-4E93-8986-5597B7242CB3Q36088750-5269A6F5-15A6-488E-9F6E-DF273BBB2F1AQ36449496-B1DB96CF-3165-489C-AE77-45A8A4F7E4BDQ39548116-B361CDE4-5FDF-4EEC-983C-EDBDE2692EE8Q39548142-3608507F-1789-4488-A8EB-AC86DEF3690FQ41178359-BF567ED1-534D-463F-B59B-3D1466A41A99Q41879525-ADF008AF-3133-4F62-9E11-C798B383133AQ46889721-D0CBB0BE-41B1-432F-A7CD-6F869E5E4599Q48373268-BE4AA07E-25A8-4F8F-9D61-DB96B66DF420Q48400379-679395A6-49E3-414D-9C8E-03C42B80A020Q48578177-8D553680-61A0-4F33-A01F-D4F1BA19578BQ48810392-37C0FD90-BB2E-4039-B305-35A14A4A9D0EQ51955321-477E262A-B3B5-4479-90EA-CA5825823FB7
P2860
Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia.
description
1983 nî lūn-bûn
@nan
1983年の論文
@ja
1983年学术文章
@wuu
1983年学术文章
@zh-cn
1983年学术文章
@zh-hans
1983年学术文章
@zh-my
1983年学术文章
@zh-sg
1983年學術文章
@yue
1983年學術文章
@zh
1983年學術文章
@zh-hant
name
Reduced cholecystokinin-like a ...... ive symptoms in schizophrenia.
@en
Reduced cholecystokinin-like a ...... ive symptoms in schizophrenia.
@nl
type
label
Reduced cholecystokinin-like a ...... ive symptoms in schizophrenia.
@en
Reduced cholecystokinin-like a ...... ive symptoms in schizophrenia.
@nl
prefLabel
Reduced cholecystokinin-like a ...... ive symptoms in schizophrenia.
@en
Reduced cholecystokinin-like a ...... ive symptoms in schizophrenia.
@nl
P2093
P1433
P1476
Reduced cholecystokinin-like a ...... ive symptoms in schizophrenia.
@en
P2093
Ferrier IN
Johnstone EC
O'Shaughnessy D
Roberts GW
P304
P356
10.1016/0024-3205(83)90797-X
P407
P577
1983-08-01T00:00:00Z